{"id":{"repo_id":"glasgow","oai_identifier":"oai:theses.gla.ac.uk:76963"},"canonical_url":"https://search.ndltd.org/etd/glasgow/oai:theses.gla.ac.uk:76963","repository":{"repo_id":"glasgow","name":"University of Glasgow","base_url":"https://theses.gla.ac.uk/cgi/oai2"},"display":{"title":"The Control of Cyclosporin in Transplantation: Pharmacokinetic Aspects","abstract":"Cyclosporin is a relatively new immunosuppressant drug which has been shown to be useful in prevention of graft rejection following organ transplantation. Its major disadvantage is its toxicity, which appears to be related to high concentrations of the drug. Low concentrations are associated with rejection episodes. The aim of cyclosporin dosing is to achieve cyclosporin concentrations which minimise both toxicity and rejection. Individualisation of therapy is necessary since cyclosporin has a narrow 'therapeutic range' and also exhibits wide pharmacokinetic variability. The aims of this work are to quantify the pharmacokinetic variability of cyclosporin in renal and liver transplant patients in an attempt to improve control of therapy.","abstract_html":"Cyclosporin is a relatively new immunosuppressant drug which has been shown to be useful in prevention of graft rejection following organ transplantation. Its major disadvantage is its toxicity, which appears to be related to high concentrations of the drug. Low concentrations are associated with rejection episodes. The aim of cyclosporin dosing is to achieve cyclosporin concentrations which minimise both toxicity and rejection. Individualisation of therapy is necessary since cyclosporin has a narrow &#x27;therapeutic range&#x27; and also exhibits wide pharmacokinetic variability. The aims of this work are to quantify the pharmacokinetic variability of cyclosporin in renal and liver transplant patients in an attempt to improve control of therapy.","abstract_has_math":false,"creators":["Niven, Alison A"],"institution":"University of Glasgow","degree_name":null,"degree_level":"PhD","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":1990,"date_issued":"1990","date_published":"1990","updated_at":"2026-11-19T08:31:33Z","subjects":[],"languages":["en"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":null,"outbound_label":null,"outbound_source":null,"record_url":null,"record_label":null,"record_kind":null,"record_source":null,"download_url":"https://theses.gla.ac.uk/76963/1/10983538.pdf","download_label":"Download PDF","download_source":"dc:identifier.uri","access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://theses.gla.ac.uk/cgi/oai2?verb=GetRecord&metadataPrefix=uketd_dc&identifier=oai%3Atheses.gla.ac.uk%3A76963","prefix":"uketd_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:creator","label":"Author","values":["Niven, Alison A"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["1990"]},{"key":"dc:date.issued","label":"Date","values":["1990"]},{"key":"dc:publisher.commercial","label":"Dc Publisher Commercial","values":["ProQuest Dissertations & Theses,"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["Department of Medicine and Therapeutics."]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Glasgow"]},{"key":"dc:relation.isreferencedby","label":"Dc Relation Isreferencedby","values":["https://theses.gla.ac.uk/76963/"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["PhD"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["en"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://theses.gla.ac.uk/76963/1/10983538.pdf"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Cyclosporin is a relatively new immunosuppressant drug which has been shown to be useful in prevention of graft rejection following organ transplantation. Its major disadvantage is its toxicity, which appears to be related to high concentrations of the drug. Low concentrations are associated with rejection episodes. The aim of cyclosporin dosing is to achieve cyclosporin concentrations which minimise both toxicity and rejection. Individualisation of therapy is necessary since cyclosporin has a narrow 'therapeutic range' and also exhibits wide pharmacokinetic variability. The aims of this work are to quantify the pharmacokinetic variability of cyclosporin in renal and liver transplant patients in an attempt to improve control of therapy."]},{"key":"dc:format","label":"Dc Format","values":["application/pdf"]},{"key":"dcterms:accessrights","label":"Dcterms Accessrights","values":["public"]},{"key":"dc:title","label":"Title","values":["The Control of Cyclosporin in Transplantation: Pharmacokinetic Aspects"]}]}],"canonical_facts":{"dc:creator":["Niven, Alison A"],"dc:date":["1990"],"dc:date.issued":["1990"],"dc:description.abstract":["Cyclosporin is a relatively new immunosuppressant drug which has been shown to be useful in prevention of graft rejection following organ transplantation. Its major disadvantage is its toxicity, which appears to be related to high concentrations of the drug. Low concentrations are associated with rejection episodes. The aim of cyclosporin dosing is to achieve cyclosporin concentrations which minimise both toxicity and rejection. Individualisation of therapy is necessary since cyclosporin has a narrow 'therapeutic range' and also exhibits wide pharmacokinetic variability. The aims of this work are to quantify the pharmacokinetic variability of cyclosporin in renal and liver transplant patients in an attempt to improve control of therapy."],"dc:format":["application/pdf"],"dc:identifier.uri":["https://theses.gla.ac.uk/76963/1/10983538.pdf"],"dc:language":["en"],"dc:publisher.commercial":["ProQuest Dissertations & Theses,"],"dc:publisher.department":["Department of Medicine and Therapeutics."],"dc:publisher.institution":["University of Glasgow"],"dc:relation.isreferencedby":["https://theses.gla.ac.uk/76963/"],"dcterms:accessrights":["public"],"dc:title":["The Control of Cyclosporin in Transplantation: Pharmacokinetic Aspects"],"dc:type":["Thesis"],"dc:type.qualificationlevel":["PhD"]},"updated_at":"2026-11-19T08:31:33Z"}